# Intrathecal Combination of Programmed Death-1 (PD-1)/Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Bispecific Antibody and Pemetrexed for Leptomeningeal Metastasis

> **NCT06762080** · PHASE1,PHASE2 · RECRUITING · sponsor: **Guangzhou Medical University** · enrollment: 36 (estimated)

## Conditions studied

- Leptomeningeal Metastasis

## Interventions

- **DRUG:** Cadonilimab (AK104)
- **DRUG:** Pemetrexed (Alimta)

## Key facts

- **NCT ID:** NCT06762080
- **Lead sponsor:** Guangzhou Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-07
- **Primary completion:** 2026-01-01
- **Final completion:** 2026-06-01
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2025-05-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06762080

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06762080, "Intrathecal Combination of Programmed Death-1 (PD-1)/Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Bispecific Antibody and Pemetrexed for Leptomeningeal Metastasis". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT06762080. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*